FDA 공인 Target therapy 약제
- 최초 등록일
- 2008.04.15
- 최종 저작일
- 2007.11
- 3페이지/ 한컴오피스
- 가격 1,000원
소개글
항암제 중 target therapy 약제들에 대한 소개
메커니즘과 적응증을 중심으로.
목차
1. Rituximab (Mabthera)
2. Tositumomab/I-131 tositumomab (Bexxar)
3. Alemtuzumab (Campath-1H)
4. Gemtuzumab ozogamicin (Mylotarg)
5. Bevacizumab (Avastin)
6. Cetuximab (Erbitux)
7. Trastuzumab (Herceptin)
8. Gefinitib (IRESSA)
9. Erlotinib (Tarceva)
10. Bortezomib (Velcade)
중략....
15. Ibritumomab Tiuxetan (Zevalin)
본문내용
1. Rituximab (Mabthera)
- Direct monoclonal antibody to CD20 on the surface of normal and malignant B lymphocyte
- Indication : CD20 positive B cell NHL
- Toxicity : hypersensitivity reaction,
infusion- related cytokine release syndrome(IRCRS), myelosuppression
2. Tositumomab/I-131 tositumomab (Bexxar)
- mechanism : The monoclonal antibody part of tositumomab is directed to the CD20
receptor located on B lymphocyte cells. This receptor is found on
some normal lymphocytes and also lymphocytes that are cancerous, as
in non–Hodgkin’s lymphoma. The antibody attaches to the CD20
receptor and kills the cells by exposing the cell to radiation (iodine
131).
- indication : patients with relapsed or refractory low grade follicular transformed
CD20-positive non-Hodgkins lymphoma who have not received
rituximab.
- toxicity : Mild to moderate “flu–like” symptoms with fever, nausea, and weakness
3. Alemtuzumab (Campath-1H)
- direct antibody to the cell-surface glycoprotein CD52 expressed on most normal and malignant B and T lymphocyte, NK cell,monocytes
- Indication : T-cell prolymphocytic leukemia, relapsed or refractory B-cell CLL
- Toxicity : immunosuppression,IRCRS, pancytopenia
참고 자료
Harrisons Principles of Internal Medicine, 16th Edition
Cecil Medicine, 23rd Ed